 DARTMOUTH, Nova Scotia CAMBRIDGE, Mass.--BUSINESS WIRE--- IMV DeliveryPlatform--IMV Inc. NASDAQ: IMV; TSX: IMV, a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that two abstracts featuring two DPX-based immunotherapies have been accepted for virtual poster presentation at the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics on October 7-10, 2021. Poster 1: Survivin pept 